These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 1985748)
1. A pilot study of intermediate-dose methotrexate and cytosine arabinoside, "spread-out" or "up-front," in continuation therapy for childhood non-T, non-B acute lymphoblastic leukemia. A Pediatric Oncology Group study. Krance RA; Newman EM; Ravindranath Y; Harris MB; Brecher M; Wimmer R; Shuster JJ; Land VJ; Pullen J; Crist W Cancer; 1991 Feb; 67(3):550-6. PubMed ID: 1985748 [TBL] [Abstract][Full Text] [Related]
2. Comparison of two schedules of intermediate-dose methotrexate and cytarabine consolidation therapy for childhood B-precursor cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Land VJ; Shuster JJ; Crist WM; Ravindranath Y; Harris MB; Krance RA; Pinkel D; Pullen DJ J Clin Oncol; 1994 Sep; 12(9):1939-45. PubMed ID: 8083715 [TBL] [Abstract][Full Text] [Related]
3. Intensive alternating drug pairs after remission induction for treatment of infants with acute lymphoblastic leukemia: A Pediatric Oncology Group Pilot Study. Lauer SJ; Camitta BM; Leventhal BG; Mahoney D; Shuster JJ; Kiefer G; Pullen J; Steuber CP; Carroll AJ; Kamen B J Pediatr Hematol Oncol; 1998; 20(3):229-33. PubMed ID: 9628434 [TBL] [Abstract][Full Text] [Related]
4. Dose intensification of methotrexate and cytarabine during intensified continuation chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: POG 9406: a report from the Children's Oncology Group. Tower RL; Jones TL; Camitta BM; Asselin BL; Bell BA; Chauvenet A; Devidas M; Halperin EC; Pullen J; Shuster JJ; Winick N; Kurtzberg J J Pediatr Hematol Oncol; 2014 Jul; 36(5):353-61. PubMed ID: 24608079 [TBL] [Abstract][Full Text] [Related]
5. Teniposide (VM-26) and continuous infusion cytosine arabinoside for initial induction failure in childhood acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study. Ochs J; Rivera GK; Pollock BH; Buchanan G; Crist W; Freeman AI Cancer; 1990 Oct; 66(8):1671-7. PubMed ID: 2208021 [TBL] [Abstract][Full Text] [Related]
6. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial. Millot F; Suciu S; Philippe N; Benoit Y; Mazingue F; Uyttebroeck A; Lutz P; Mechinaud F; Robert A; Boutard P; Marguerite G; Ferster A; Plouvier E; Rialland X; Behard C; Plantaz D; Dresse MF; Philippet P; Norton L; Thyss A; Dastugue N; Waterkeyn C; Vilmer E; Otten J; J Clin Oncol; 2001 Apr; 19(7):1935-42. PubMed ID: 11283125 [TBL] [Abstract][Full Text] [Related]
7. Unexpected acute neurologic toxicity in the treatment of children with acute lymphoblastic leukemia. Winick NJ; Bowman WP; Kamen BA; Roach ES; Rollins N; Jacaruso D; Buchanan GR J Natl Cancer Inst; 1992 Feb; 84(4):252-6. PubMed ID: 1734087 [TBL] [Abstract][Full Text] [Related]
8. Intensive alternating drug pairs for treatment of high-risk childhood acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study. Lauer SJ; Camitta BM; Leventhal BG; Mahoney DH; Shuster JJ; Adair S; Casper JT; Civin CI; Graham M; Kiefer G Cancer; 1993 May; 71(9):2854-61. PubMed ID: 8467463 [TBL] [Abstract][Full Text] [Related]
9. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica. Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi AM; Messina C; Mori PG; Miniero R; Colella R; Basso G J Clin Oncol; 1995 Oct; 13(10):2497-502. PubMed ID: 7595699 [TBL] [Abstract][Full Text] [Related]
10. Intermediate-dose intravenous methotrexate and mercaptopurine therapy for non-T, non-B acute lymphocytic leukemia of childhood: a Pediatric Oncology Group study. Camitta B; Leventhal B; Lauer S; Shuster JJ; Adair S; Casper J; Civin C; Graham M; Mahoney D; Munoz L J Clin Oncol; 1989 Oct; 7(10):1539-44. PubMed ID: 2778483 [TBL] [Abstract][Full Text] [Related]
11. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy--a Pediatric Oncology Group study. Mahoney DH; Shuster JJ; Nitschke R; Lauer SJ; Steuber CP; Winick N; Camitta B J Clin Oncol; 1998 May; 16(5):1712-22. PubMed ID: 9586883 [TBL] [Abstract][Full Text] [Related]
12. Intensification with intermediate-dose intravenous methotrexate is effective therapy for children with lower-risk B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group study. Mahoney DH; Shuster JJ; Nitschke R; Lauer S; Steuber CP; Camitta B J Clin Oncol; 2000 Mar; 18(6):1285-94. PubMed ID: 10715299 [TBL] [Abstract][Full Text] [Related]
13. Effects of cranial radiation in children with high risk T cell acute lymphoblastic leukemia: a Pediatric Oncology Group report. Laver JH; Barredo JC; Amylon M; Schwenn M; Kurtzberg J; Camitta BM; Pullen J; Link MP; Borowitz M; Ravindranath Y; Murphy SB; Shuster J Leukemia; 2000 Mar; 14(3):369-73. PubMed ID: 10720128 [TBL] [Abstract][Full Text] [Related]
14. Intensive oral methotrexate protects against lymphoid marrow relapse in childhood B-precursor acute lymphoblastic leukemia. Winick N; Shuster JJ; Bowman WP; Borowitz M; Farrow A; Jacaruso D; Buchanan GR; Kamen BA J Clin Oncol; 1996 Oct; 14(10):2803-11. PubMed ID: 8874342 [TBL] [Abstract][Full Text] [Related]
15. Treatment of occult or late overt testicular relapse in children with acute lymphoblastic leukemia: a Pediatric Oncology Group study. Wofford MM; Smith SD; Shuster JJ; Johnson W; Buchanan GR; Wharam MD; Ritchey AK; Rosen D; Haggard ME; Golembe BL J Clin Oncol; 1992 Apr; 10(4):624-30. PubMed ID: 1548525 [TBL] [Abstract][Full Text] [Related]
16. [Results of the CCLSG high risk ALL 874 protocol in childhood acute lymphoblastic leukemia. Children's Cancer and Leukemia Study Group]. Kawai S; Fujimoto T; Zha Z; Asami K; Oka T; Kaneko Y; Takaue Y; Ninomiya T; Nishikawa K; Tsuchiya T Rinsho Ketsueki; 1993 Feb; 34(2):128-36. PubMed ID: 8492409 [TBL] [Abstract][Full Text] [Related]
17. Favorable outcome of B-cell acute lymphoblastic leukemia in childhood: a report of three consecutive studies of the BFM group. Reiter A; Schrappe M; Ludwig WD; Lampert F; Harbott J; Henze G; Niemeyer CM; Gadner H; Müller-Weihrich S; Ritter J Blood; 1992 Nov; 80(10):2471-8. PubMed ID: 1421370 [TBL] [Abstract][Full Text] [Related]